Rare disease news

FDA approvals, research breakthroughs, clinical trials, and advocacy updates

Curated and summarized by AI for patients and caregivers

AllDrug approvalsClinical trialsResearchGrants & fundingAdvocacy & policyPipeline
Show:All newsBreaking onlyImportant & breaking
Date:7 days30 days90 daysAll time

1 article matching "NON RARE IN EUROPE: Alzheimer disease"

🔴 BreakingDrug approvalRSSApr 30

FDA Approves First Non-Antipsychotic Drug to Treat Agitation Associated with Dementia

The FDA has approved a new medication called Auvelity to help calm agitation in people with Alzheimer's disease dementia. This is the first non-antipsychotic drug approved for this specific use, meaning it works differently than older medications that were previously used. Agitation is a common and difficult symptom in Alzheimer's patients, so this new option gives doctors another tool to help manage it.

WHY IT MATTERSThis approval offers Alzheimer's patients and caregivers a new treatment option that may help reduce agitation without the side effects associated with traditional antipsychotic medications.
💬 Ask your doctorAlzheimer's diseaseRead →

Get personalized rare disease news

Follow your conditions to see news about the diseases that matter to you — FDA approvals, trial openings, and research breakthroughs.

Create free account →Browse diseases